… Heart failure (HF) treatment has changed substantially over … Mortality and Morbidity in Heart
Failure) randomized controlled … efficacy and safety in clinical trials and daily clinical practice. …

Aims We sought to conduct a meta‐analysis regarding the safety and efficacy of sodium‐glucose
co‐transporter 2 (SGLT2) inhibitors in patients with heart failure (HF). Methods and …

… young compared with the general population with heart failure and did not have heart
failure with preserved left ventricular function (or diastolic heart failure). The only measure of …

Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide.
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the …

Background Heart failure (HF) and chronic obstructive pulmonary disease (COPD) frequently
coexist, with undefined prognostic and therapeutic implications. We investigated clinical …

… and 72 h, worsening or persistent heart failure, over-diuresis, … heart failure was defined as
the need for rescue therapy due to persistent or worsening signs and symptoms of heart failure…

… worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail.
… or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart …

… We explore the safety and efficacy of rivaroxaban in patients with heart failure (HF). … In this
analysis, the primary efficacy and safety treatment effects were similar between patients with …

… with concomitant heart failure and CKD is increasing. Hence, it is important to understand
whether current standard therapies have a similar degree of efficacy and safety profiles in HF …

… the relative efficacy and safety of … the efficacy and safety of NOACs in patients with AF and
HF enrolled in all phase III NOACs clinical trials and to detect whether the efficacy and safety of …